Dr. François Emond completed his medical degree at Laval University in 1997 and his residency in adult neurology in 2002. After a clinical fellowship in multiple sclerosis at The Ottawa Hospital under the direction of Dr. Mark S. Freedman, he joined the neurology department of the CHU of Quebec-Hôpital de l’Enfant-Jésus. Since 2012, he has been director of the multiple sclerosis clinic at the CHU of Quebec and IRDPQ (CIUSSS Capitale-Nationale – François-Charron Centre). In addition to following several hundred patients with multiple sclerosis, he regularly participates in teaching students, externs and residents of the RUIS-Laval network.
Since 2003, Dr. Emond has been involved, as primary local investigator or co-investigator, in multiple clinical trials on the long-term treatment of multiple sclerosis.
Département des sciences neurologiques
Canada G1J 1Z4
Data not available
Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches.Journal Article
Neural Regen Res, 13 (11), pp. 1871-1874, 2018, ISSN: 1673-5374.
Safety and efficacy of venoplasty in MS: A randomized, double-blind, sham-controlled phase II trial.Journal Article
Neurology, 91 (18), pp. e1660-e1668, 2018, ISSN: 0028-3878.
Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatment.Journal Article
Curr Med Res Opin, 34 (8), pp. 1419-1430, 2018, ISSN: 0300-7995.
Pulvinar sign in a case of anti-HU paraneoplastic encephalitis.Journal Article
Neuroradiol J, 29 (6), pp. 436-439, 2016, ISSN: 1971-4009.
Treatment optimization in MS: Canadian MS Working Group updated recommendations.Journal Article
Can J Neurol Sci, 40 (3), pp. 307-23, 2013, ISSN: 0317-1671.
LRRK2 is not a significant cause of Parkinson's disease in French-Canadians.Journal Article
Can J Neurol Sci, 34 (3), pp. 333-5, 2007, ISSN: 0317-1671.
- Centre hospitalier universitaire de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31